Product Description
DYNE-101 consists of a proprietary Fab conjugated with our linker to an antisense oligonucleotide (ASO). (Sourced from: https://www.dyne-tx.com/pipeline/)
Mechanisms of Action: DMPK Reducer
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: Fast Track - Myotonic Dystrophy Type 1Orphan Drug - Myotonic Dystrophy|Myotonic Dystrophy Type 1 *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dyne Therapeutics
Company Location: WALTHAM MA 02451
Company CEO: Joshua Brumm
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: France, Germany, Italy, Netherlands, New Zealand, United Kingdom
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Myotonic Dystrophy Type 1
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACHIEVE | P2 |
Recruiting |
Myotonic Dystrophy Type 1 |
2029-07-01 |
|
| 2023-510353-42-00 | P2 |
Unknown Status |
Myotonic Dystrophy Type 1 |
2027-09-01 |
|
| ACHIEVE Study | P2 |
Active, not recruiting |
Myotonic Dystrophy Type 1 |
2027-05-26 |